melphalan
information and resources from the National Cancer Institute
NCI Thesaurus | melphalan
An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. NCI Thesaurus | melphalan
An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.
|
|
|
|
news articles
Thalidomide Improves Chemotherapy Efficacy in Elderly With ... Mar 10, 2006
Cancerpage.com, NEW YORK MAR 09, 2006 (Reuters Health) - In elderly patients with multiple myeloma, adding thalidomide to standard treatment with melphalan and prednisone ...
Thalidomide Beneficial in Multiple Myeloma Patients Ineligible for ... Mar 10, 2006
Cancer Consultants (press release), According to an article recently published in the Lancet, the addition of thalidomide to melphalan (Alkeran®) and prednisone appears beneficial in the ...
Thalidomide shows promise for ALS Mar 11, 2006
Monsters and Critics.com, Lancet, Antonio Palumbo of the University of Torino in Italy and colleagues found that patients who were given thalidomide on top of melphalan and prednisone ...
No Long Term Vascular Damage After Isolated Limb Perfusion and ... Mar 27, 2006
DG News SAN DIEGO, CA -- March 27, 2006 -- Isolated limb perfusion with tumor necrosis factor alpha (TNF alpha) and melphalan followed by surgical resection and ...
Isolated Limb Perfusion with TNF and Alkeran® Spares Limbs in ... Mar 22, 2006
Cancer Consultants (press release), ...in an early online edition of the journal Cancer, isolated limb perfusion with tumor necrosis factor and the chemotherapy agent Alkera® (melphalan) results in ...
US Study Fails to Confirm Benefits of Autologous Stem Cell ... Mar 14, 2006
Cancer Consultants (press release), Most randomized trials using high-dose melphalan regimens have shown improved disease-free and overall survival compared to standard chemotherapy for younger ...
Thalidomide helps blood cancer cases Mar 9, 2006
The Age, ...a trial involving 255 patients, researchers led by Dr Antonio Palumbo of the University of Turin found those treated with thalidomide, melphalan and prednisone ...
Thalomid With Chemotherapy Helps Older Myeloma Patients Mar 10, 2006
MedPage Today, Adding Thalomid to oral Alkeran (melphalan) and prednisone improved response rates for patients ages 60 to 85 and extended event-free survival, Antonio Palumbo ...
Thalidomide Treatment for Multiple Myeloma Mar 9, 2006
Ivanhoe, They found patients treated with melphalan, prednisone, and thalidomide (MPT) responder better and lived event-free longer than those treated with melphalan ...
Adding Thalidomide to Myeloma Therapy of Little Benefit Mar 9, 2006
Cancerpage.com, ...new research shows. Melphalan-based high-dose therapy has been shown to improve the survival of multiple myeloma. However, it was ...
High-Dose Therapy Does Not Improve Multiple Myeloma Outcome Mar 9, 2006
Cancerpage.com, They received melphalan and total-body irradiation and allotransplantation or standard chemotherapy with vincristine, carmustine, cyclophosphamide, melphalan ...
Thalidomide Should Be Added To Treatment Combination For Multiple ... Mar 13, 2006
Medical News Today (press release), ...cells. Since 1960 oral melphalan and prednisone (MP) have been regarded as the standard of care in elderly multiple myeloma patients. ...
Thalidomide and Hematopoietic-Cell Transplantation for Multiple ... Mar 8, 2006
New England Journal of Medicine (subscription), Crowley, Ph.D. Background High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed ...
Thalidomide Not Associated with Survival Improvement in Multiple ... Mar 13, 2006
Cancer Consultants (press release), ...patients receive induction therapy with VAD (vincristine, Adriamycin and dexamethasone) followed by single or tandem transplants with high-dose melphalan. ...
Delcath Systems Announces Initial Patient Treatment In Phase III ... Mar 1, 2006
PharmaLive.com (press release), System in its pivotal Phase III clinical trial for the treatment of metastatic melanoma in the liver using the Delcath system with melphalan, an approved ...
Isolated Limb Perfusion with Tumor Necrosis Factor and Alkeran® ... Mar 21, 2006
Cancer Consultants (press release), Researchers from the Netherlands have reported that isolated limb perfusion with tumor necrosis factor-alfa (TNF-alfa) and Alkeran (melphalan) can provide limb ...
Thalidomide Gives Boost to Myeloma Therapy Mar 8, 2006
Forbes ...doctors at the institute are routinely treating multiple myeloma patients with thalidomide as part of a regimen that includes the drug melphalan along with ...
Experts Debate Thalidomide's Promise Against Myeloma Mar 10, 2006
Forbes An Italian team at the University of Turin added thalidomide to standard therapy (melphalan plus prednisone) for newly diagnosed cases of the blood cancer in ...
Thalidomide Not Associated with Survival Improvement in Multiple ... Mar 9, 2006
Playfuls.com, All patients were treated with melphalan-based intensive chemotherapy followed by autologous stem cell transplantation; approximately half of the patients also ...
Thalidomide improves remission in myeloma Mar 9, 2006
News-Medical.net, The results arose from the addition of thalidomide to a myeloma treatment regimen that included high-dose, melphalan-based chemotherapy in a setting of tandem ...
No Survival Advantage for Thalomid in Multiple Myeloma Mar 9, 2006
MedPage Today, ...the New England Journal of Medicine, 668 patients with newly diagnosed multiple myeloma received two cycles of intensive Alkeran (melphalan)-based chemotherapy ...
Delcath Systems initiates phase III trial in melanoma Mar 2, 2006
Pharmaceutical Business Review ...the body from excessive toxicity. The system will be tested with melphalan, an approved anticancer agent. The company says that ...
Thalomid® in Induction Improves Response Rates in Elderly with ... Mar 14, 2006
Cancer Consultants (press release), ...randomized trial has determined that elderly patients with multiple myeloma treated with Thalomid (thalidomide) in addition to melphalan and prednisone (MP ...
New England Journal of Medicine Publishes Research By UAMS Team on ... Mar 8, 2006
Yahoo! News (press release) ...for Multiple Myeloma" showed results from the addition of thalidomide to a myeloma treatment regimen that included high-dose, melphalan-based chemotherapy in a ...
New England Journal of Medicine Publishes Research by UAMS Team on ... Mar 9, 2006
PR Web (press release), ...ref&siteid=nejm) showed results from the addition of thalidomide to a myeloma treatment regimen that included high-dose, melphalan-based chemotherapy in a ...
Doxil® in the VAD Regimen for Myeloma Confirmed Less Toxic Than ... Feb 28, 2006
Cancer Consultants (press release), ...transplantation. This is because this is a less marrow-toxic regimen than the more conventional Alkeran®-(melphalan) based regimens. ...
BOULDER, Colorado, December 13 /PRNewswire/ -- Dec 13, 2005
ITNews, An analysis of data from a multi-center trial of 255 patients comparing the efficacy and toxicity of the combination of oral melphalan and prednisone (MP) to ...
Adding Radioimmunotherapy To Chemotherapy Reduces Relapse Risk In ... Dec 17, 2005
Medical News Today (press release), ...had their stem cells collected, but received a lower (standard) dose of Zevalin, followed by chemotherapy with BEAM (BCNU, etoposide, cytarabine and melphalan ...
Natco Pharma launches blood cancer drug Dec 8, 2005
India Infoline.com, Natco Pharma Ltd. on Thursday announced the launch of its brand, Alphalan (Melphalan) in 2 mg and 5 mg tablet forms. The launch ...
Delcath Systems Announces Extension of Warrants Dec 19, 2005
dBusinessNews Hartford (press release), In May 2005, Delcath received fast-track status from the US FDA for the treatment of metastatic melanoma in the liver with melphalan, an approved anticancer ...
Delcath Receives Additional US Patent for Cancer Treatment System Dec 8, 2005
Yahoo! News (press release) ...we continue our current trials and move toward beginning our fast-track Phase III clinical trials for the treatment of liver cancer using melphalan," Koly added ...
Consistently High Complete and Overall Response Rates in Newly ... Dec 13, 2005
PR Newswire (press release), ...consistently high complete response rates provide evidence to support VELCADE as the backbone of therapy." VELCADE Combination with Melphalan and Prednisone ...
ATLANTA -- Abstracts Presented at 2005 ASH Annual Meeting Reveal ... Dec 14, 2005
dBusinessNews Atlanta (press release), ...etoposide. The second study was a phase I/II trial of standard dose ZEVALIN and BEAM (BCNU, cytarabine, etoposide, melphalan). No ...
Consistently High Complete and Overall Response Rates in Newly ... Dec 13, 2005
Biotech Intelligence (press release), ...of Salamanca in Spain and conducted within the Spanish Myeloma Group (GEM/PETHEMA), evaluated the safety and efficacy of VELCADE plus melphalan and prednisone ...
Delcath dealt another patent for chemotherapy delivery system Dec 8, 2005
Boston Mass High Tech, Delcath received fast-track status from the US Food and Drug Administration for the treatment of metastatic melanoma in the liver with melphalan, an approved ...
Age Makes Little Difference in Outcomes for Non-Hodgkin's Lymphoma ... Dec 12, 2005
DG News ...and underwent autologous stem cell transplant following BEAM conditioning, which combines BCNU (carmustine), etoposide, cytosine arabinoside, and melphalan. ...
Geron Announces Data on the Effects of Its Cancer Drug, GRN163L ... Dec 12, 2005
PharmaLive.com (press release), ...subcutaneous mouse model showed significant tumor growth inhibition with GRN163L alone and enhanced anti-tumor activity when used in combination with Melphalan ...
New Data on VELCADE(R) (bortezomib) for Injection to Be Presented ... Dec 6, 2005
PR Newswire (press release), ...of peripheral neuropathy (abstract #3336) * Single-agent or combination therapy in the front-line setting -- Combination with melphalan and prednisone ...
Delcath Receives Canadian Patent for Novel Apparatus and Method ... Nov 21, 2005
PR Newswire (press release), ...liver cancer." In May of 2005, Delcath received fast-track status from the US FDA for treating metastatic melanoma in the liver with melphalan, a currently ...
|
|
